BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-502@pharmaconomics
DTSTAMP:20260707T015522Z
DTSTART;VALUE=DATE:20251001
DTEND;VALUE=DATE:20251002
SUMMARY:TECX Phase 1 — TX45
DESCRIPTION:Phase 1 trial results for TX45 in Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (PH-HFrEF) are due Oct 1\, 2025. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1681087/000119312526076843/tecx-ex99_1.htm\n\nTrack it: https://pharmaconomics.com/e/502
URL:https://pharmaconomics.com/e/502
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:TECX catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR